166 related articles for article (PubMed ID: 37865067)
21. Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study.
Sabet Z; Vagiannis D; Budagaga Y; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430819
[TBL] [Abstract][Full Text] [Related]
22. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
23. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update.
Engle K; Kumar G
Eur J Med Chem; 2022 Sep; 239():114542. PubMed ID: 35751979
[TBL] [Abstract][Full Text] [Related]
24. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
25. ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
Wu CP; Hung CY; Hsieh YJ; Murakami M; Huang YH; Su TY; Hung TH; Yu JS; Wu YS; Ambudkar SV
Cells; 2023 Mar; 12(7):. PubMed ID: 37048130
[TBL] [Abstract][Full Text] [Related]
26. Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.
Nazari S; Mosaffa F; Poustforoosh A; Mortazavi M; Saso L; Firuzi O; Moosavi F
Toxicol Appl Pharmacol; 2024 Mar; 484():116866. PubMed ID: 38367674
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
28. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
29. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
30. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Yang D; Kathawala RJ; Chufan EE; Patel A; Ambudkar SV; Chen ZS; Chen X
Future Oncol; 2014 Aug; 10(11):1827-41. PubMed ID: 24295377
[TBL] [Abstract][Full Text] [Related]
31. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
32. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
[TBL] [Abstract][Full Text] [Related]
33. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
[TBL] [Abstract][Full Text] [Related]
35. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
36. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
[TBL] [Abstract][Full Text] [Related]
37. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy.
Wu CP; Hsieh CH; Wu YS
Mol Pharm; 2011 Dec; 8(6):1996-2011. PubMed ID: 21770407
[TBL] [Abstract][Full Text] [Related]
38. New uracil analog as inhibitor/modulator of ABC transporters or/and NF-κB in taxol-resistant MCF-7/Tx cell line.
Długosz-Pokorska A; Janecki T; Janecka A; Gach-Janczak K
J Cancer Res Clin Oncol; 2024 Jun; 150(6):328. PubMed ID: 38914845
[TBL] [Abstract][Full Text] [Related]
39. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]